Shares of Moderna are falling Thursday. The company made two significant announcements regarding its finances and business ...

Moderna ($MRNA) steps into Thursday’s analyst day with more pressure than momentum. The stock is down more than 40% this year ...

Moderna, Inc. (MRNA) is a biotechnology firm based in Cambridge, Massachusetts, that focuses on mRNA technology to create innovative medicines and vaccines. The company’s operations encompass ...

The company’s portfolio includes two products: Covid-19 vaccine and RSV vaccine (approved only in May 2024). However the company does have a promising pipeline. Moderna has shown promising clinical ...

Multiple analysts have issued price targets for $MRNA recently. We have seen 10 analysts offer price targets for $MRNA in the last 6 months, with a median target of ...

Moderna (MRNA) stock gains as the firm projects 10% growth for next year ahead of the consensus as it plans to conduct the Analyst Day event on Thursday. Read more here.

Moderna ( (MRNA)) has provided an update. On November 12, 2025, Moderna, Inc. held a Special Meeting of Shareholders where two proposals were approved. The first was a one-time stock option exchange ...

Wealthfront Advisers LLC lowered its stake in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 84.4% during the fourth quarter, according to the company in its most recent disclosure with the ...

Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.